SCHEMBL5089204

SCHEMBL5089204

CCOC(=O)Nc1ccc(OCc2ccc(C(=O)OC)cc2)cc1N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LNPEP Q9UIQ6 4/20 0.55
MAPT P10636 5/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CYP3A4 P08684 1/20 0.51
KCNH2 Q12809 1/20 0.51
KCNQ2 O43526 2/20 0.49
KCNQ3 O43525 1/20 0.49
KCNQ4 P56696 1/20 0.49
KCNQ5 Q9NR82 1/20 0.49
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
ERAP2 Q6P179 1/20 0.47
KDM4E B2RXH2 1/20 0.45
APAF1 O14727 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5089465 0.89 CYP1A2 (0.55) LNPEPMAPTKMT2AMEN1SMN1; SMN2
SCHEMBL5087377 0.86 MAOA (0.52) KMT2ASMN1; SMN2KCNQ2KCNQ3KCNQ4
SCHEMBL5090811 0.86 KCNQ2 (0.65) MAPTKMT2AMEN1SMN1; SMN2CYP3A4
SCHEMBL5090320 0.86 ALDH1A1 (0.53) LNPEPNPC1RAB9AKMT2AMEN1
SCHEMBL5090177 0.84 KCNQ2 (0.49) LNPEPKMT2AMEN1SMN1; SMN2CYP3A4
SCHEMBL5090265 0.83 RAB9A (0.51) LNPEPRAB9ASMN1; SMN2CYP3A4KCNQ2
SCHEMBL5087380 0.83 KCNQ2 (0.57) KMT2AMEN1CYP3A4KCNQ2KCNQ3
SCHEMBL5090792 0.83 KCNQ2 (0.55) SMN1; SMN2CYP3A4KCNH2KCNQ2KCNQ3
SCHEMBL5090790 0.82 KCNQ2 (0.49) LNPEPMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL5090791 0.82 KCNQ2 (0.59) MAPTNPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS JPMORGAN CHASE BANK, N.A. 2008-08-07 US claimed
US-8722929-B2 N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2014-05-13 US disclosed
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS JPMORGAN CHASE BANK, N.A. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188561-A1 N-[2-AMINO-4-(PHENYLMETHOXY)PHENYL] AMIDES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS KCNB2, KCNJ2, KCNA2 LNPEP 2911/4885MAPT 1184/4885NPC1 536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.